Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC
LUBBOCK, Texas, Sept. 19, 2014 /PRNewswire/ -- Kiromic, LLC, a Lubbock bio-pharmaceutical company, announced today the addition of Kent Hance, the former chancellor of Texas Tech University, to its board as the vice chairman. Hance retired as chancellor in July 2014, after raising $1.2 billion for the university.
"Kiromic is pleased to announce that Kent Hance, the most successful chancellor in the history of Texas Tech University, has joined the Kiromic team not only as an investor, but also as our new vice chairman of the board. Kent will add immensely valuable experience in the political, commercial, legal, and regulatory arenas, as Kiromic continues to establish itself as one of the world's leading immunotherapy R&D firms," said Scott Dahlbeck, MD, Pharm.D., CEO of Kiromic.
"Kiromic has a bright future. They are on the cutting edge of cancer research in immunotherapy. I am proud to work with some of the brightest scientists in the world," said Hance.
Hance, as chancellor, oversaw the administration of Texas Tech University, Texas Tech University Health Sciences Center in Lubbock, the Texas Tech University Health Sciences Center in El Paso, and Angelo State University in San Angelo, Texas. University regents voted to name him chancellor-emeritus upon his retirement.
Hance served in the state senate from 1975 to 1979, the U.S. Congress from 1979 to 1985, and on the Texas Railroad Commission from 1987 to 1990. In 1981 Hance carried and passed President Reagan's tax cut. The tax cut remains the largest tax cut in history.
Kiromic's mission is to restore the lives of cancer patients through the research and discovery of new diagnostic and therapeutic products. Kiromic researchers have discovered a group of cancer-related proteins that are designed to safely awaken the body's immune system to effectively attack and remove cancer cells, and yet spare normal cells and tissues. In February 2014, the FDA gave approval to Kiromic to begin phase I/II clinical trials of its DC vaccine platform, one of the many products in its large immunotherapy product pipeline.
For further information about Kent Hance and Kiromic, please visit www.kiromic.com.
About Kiromic, LLC: Kiromic, an NIH funded company, offers diagnostic and therapeutic immunotherapy and small molecule products primarily in the field of oncology, but also with potential applications in cardiology and peripheral vascular disease. The company's diverse capabilities allow it to independently research new methods of cancer diagnosis and treatment, perform clinical trials, and continue to expand and develop its growing product pipeline.
Photo - http://photos.prnewswire.com/prnh/20140919/147303
SOURCE Kiromic, LLC
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article